Critical Questions in Choosing EGFR-Targeted Therapies for NSCLC - Episode 6

Role of Rebiopsy at Disease Progression in EGFRm NSCLC

,

Panelists discuss how second-line therapy after osimertinib monotherapy depends on resistance mechanisms. If MET amplification, consider MET inhibitors plus EGFR tyrosine kinase inhibitors (TKIs). For C797S mutation, potential options include first- or third-generation EGFR TKI combinations. Chemotherapy remains a key fallback.

EP. 1: Brief Overview of the Treatment Landscape of First-Line EGFRm NSCLC
EP. 2: FLAURA, FLAURA2, and MARIPOSA: Key Takeaways to Impact First-Line Treatment Approach
EP. 3: Clinical Factors to Consider When Choosing a Treatment Strategy
EP. 4: Treatment Strategies to Manage AEs in EGFRm NSCLC
EP. 5: The Multidisciplinary Team’s Role in EGFRm NSCLC Management
Now Viewing
EP. 6: Role of Rebiopsy at Disease Progression in EGFRm NSCLC
EP. 7: Treatment Sequencing in Disease Progression in EGFRm NSCLC
EP. 8: Looking Into the Future and at Unmet Needs in EGFRm NSCLC

Video content above is prompted by the following:

Regarding treatment sequencing, how do you approach second-line therapy after osimertinib monotherapy?

Related Content:

Critical Questions in Choosing EGFR-Targeted Therapies for NSCLCVideo SeriesClinicalInsights
Key Messages From the Breast Cancer ADC Data Set and Closing Remarks
Treatment Duration, Maintenance Concepts, and Development of New ADC Targets in Breast
Combination Approaches With ADCs and Emerging Clinical Strategies in Breast Cancer